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Background: Riociguat was well tolerated and improved exercise and functional capacity in patients with
pulmonary arterial hypertension (PAH) and inoperable chronic thromboembolic pulmonary hyperten-
sion (CTEPH) in a 12-week Phase II trial. We present ﬁnal data from the long-term extension phase of this
study.
Methods: During this multicenter, open-label, uncontrolled long-term extension study, riociguat dose
could be changed at the physician's discretion (range 0.5e2.5 mg three times daily). The primary
outcome was long-term safety and tolerability of riociguat; secondary outcomes included 6-minute
walking distance, World Health Organization functional class, survival, and clinical worsening-free
survival.
Results: Sixty-eight patients (inoperable CTEPH, n ¼ 41; PAH, n ¼ 27) entered the long-term extension.
Median treatment duration at the ﬁnal data cut-off was 77 months. The most common adverse events
were nasopharyngitis (57%) and peripheral edema (37%). Three patients (4%) experienced serious
adverse events of hemoptysis: two moderate, one severe, none fatal or considered drug-related. At
Month 48, 6-minute walking distance increased from baseline by 69 ± 105 m, and World Health Or-
ganization functional class improved/stabilized/worsened versus baseline in 50/45/5% of patients. Three-
year survival and clinical worsening-free survival were 91% and 49%, respectively (with patients censored
if they withdrew without experiencing an event). Starting a new PAH treatment was the most frequent
clinical worsening event.; AE, adverse event; CTEPH, chronic thromboembolic pulmonary hypertension; ERA, endothelin receptor antagonist;
, N-terminal prohormone of brain natriuretic peptide; PAH, pulmonary arterial hypertension; PDE5, phosphodiesterase
ary hypertension; SAE, serious adverse event; SD, standard deviation; sGC, soluble guanylate cyclase; tid, three times
l class.
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M. Halank et al. / Respiratory Medicine 128 (2017) 50e56 51Conclusions: Improvements in exercise and functional capacity were maintained at 4 years in patients
remaining on treatment, with no new safety signals identiﬁed. These data support riociguat as a long-
term treatment option for PAH and inoperable CTEPH.
Trial registered at: ClinicalTrials.gov.
Registration number: NCT00454558.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Pulmonary arterial hypertension (PAH) and chronic thrombo-
embolic pulmonary hypertension (CTEPH) are serious and pro-
gressive diseases, characterized by an increase in pulmonary
vascular resistance, which can ultimately lead to death due to right
heart failure [1]. PAH is caused by remodeling of the small pul-
monary arteries, whereas CTEPH is a result of obstructive throm-
boembolic material in the pulmonary vasculature, though CTEPH
can also have a distal vascular remodeling component similar to
that observed in idiopathic PAH [2,3].
PAH is primarily treated pharmacologically, and therapies
include prostanoids, endothelin receptor antagonists (ERAs),
phosphodiesterase type 5 (PDE5) inhibitors, and the soluble gua-
nylate cyclase (sGC) stimulator riociguat [1,4]. For CTEPH, pulmo-
nary endarterectomy (PEA) is the gold standard treatment as it is
potentially curative [1,2,5]. However, approximately one-third of
patients are considered inoperable, and others develop persistent/
recurrent PH following PEA [6e12]. Such patients may beneﬁt from
pharmacologic therapy [1,13].
The sGC stimulator riociguat is approved for the treatment of
both PAH and inoperable or persistent/recurrent CTEPH [1]. Rioci-
guat has a dual mode of action, sensitizing sGC to endogenous nitric
oxide (NO) and directly stimulating sGC independently of NO. This
results in increased production of cyclic guanosine mono-
phosphate, leading to vasodilation and anti-inﬂammatory, anti-
proliferative, and anti-ﬁbrotic effects [14].
In a 12-week, open-label, uncontrolled, Phase II trial in patients
with PAH or inoperable CTEPH, riociguat was well tolerated and led
to clinically relevant improvements in 6-minute walking distance
(6MWD), World Health Organization functional class (WHO FC),
and hemodynamic parameters [15]. Here we present the ﬁnal
safety and efﬁcacy data from the long-term extension (LTE) phase
of this study, with a median riociguat treatment duration of >6
years, in which we hypothesized that the beneﬁts of riociguat seen
in the initial phase of the study would continue into the LTE.2. Materials and methods
2.1. Study design and patients
This was a multicenter, open-label, uncontrolled study per-
formed in 13 of the 15 centers across Germany that participated in
the initial 12-week Phase II study. Full details of inclusion and
exclusion criteria have been reported elsewhere [15]. In brief, pa-
tients with PAH or inoperable CTEPH (WHO FC II/III, mean pul-
monary vascular resistance >300 dyn s$cm5, and mean
pulmonary arterial pressure 25 mmHg) who had successfully
completed the initial 12-week study were invited to participate in
the LTE. During the initial 12-week study, the riociguat dose was
individually adjusted over a period of 8 weeks from a starting dose
of 1 mg three times daily (tid) to a maximum of 2.5 mg tid, ac-
cording to systolic blood pressure and signs and symptoms of hy-
potension [15]. During the LTE, the dose of riociguat could bechanged at the discretion of the physician within the range of
0.5 mg tid to 2.5 mg tid.
The use of established therapy with ERAs in patients with PAH
was permitted at entry into the initial 12-week study, and general
supportive therapy with diuretics, anticoagulants, and calcium
channel blockers was permitted in all patients. During the LTE,
patients were permitted to receive add-on therapy with ERAs or
prostanoids at the discretion of the study investigator. NO donors
and speciﬁc or non-speciﬁc PDE5 inhibitors were not permitted.
The study was carried out in accordance with Good Clinical
Practice Guidelines and the Declaration of Helsinki, and is regis-
tered at ClinicalTrials.gov (NCT00454558). The study protocol was
approved by the ethics committees of all participating centers and
all patients gave written informed consent.
2.2. Outcomes
The primary outcome was the long-term safety and tolerability
of riociguat. Secondary outcomes included 6MWD, WHO FC, sur-
vival, and clinical worsening-free survival. Clinical worsening was
deﬁned as any of the following events: death, heart/lung trans-
plantation, atrial septostomy, PEA, or start of new treatment for
pulmonary hypertension (PH). No invasive hemodynamic assess-
ment was planned as part of the study protocol.
2.3. Statistical analysis
Statistical analyses in this uncontrolled exploratory trial were
descriptive and no formal statistical sample size estimation was
performed. The SAS® software package (SAS Institute, Cary, NC,
USA) was used for statistical evaluation.
All patients entering the LTE were included in the safety
assessment. AEs in the LTE were deﬁned as any AE starting or
worsening after the ﬁrst dose of LTE study medication, up until 30
days after treatment was stopped.
6MWD, WHO FC, modiﬁed Borg dyspnea, and NT-proBNP data
are presented to Month 48, after which patient numbers were too
low for meaningful analysis. Only patients remaining on riociguat
at the respective timepoints were included in these analyses;
missing data were not imputed. Survival, clinical worsening-free
survival, time to addition of concomitant PH treatment, and time
to discontinuation were analyzed using KaplaneMeier plots up to
Month 76. For the survival and clinical worsening-free survival




Sixty-eight patients entered the LTE (Fig. 1), of whom 41 had
inoperable CTEPH and 27 had PAH. Baseline characteristics at entry
into the LTE are shown in Table 1. As observed at the start of the
initial 12-week study [15], baseline 6MWDwas somewhat lower in
Fig. 1. Patient disposition.
CTEPH ¼ chronic thromboembolic pulmonary hypertension; LTE ¼ long-term extension; PAH ¼ pulmonary arterial hypertension.
aTwo additional patients (one with PAH and one with CTEPH) died after discontinuing riociguat.
Table 1
Baseline characteristics in patients entering the LTE.
Characteristic PAH (n ¼ 27) CTEPH (n ¼ 41) Total (n ¼ 68)
Age, years 56.1 (19e73) 61.6 (37e76) 59.4 (19e76)
Ethnic origin white 27 (100) 41 (100) 68 (100)
Female 20 (74) 18 (44) 38 (56)
Body mass index, kg/m2 26.9 (18.6e38.1) 25.6 (17.0e33.3) 26.1 (17.0e38.1)
6MWD, m 406.7 (150e630) 447.6 (260e727)a 430.9 (150e727)b
WHO FC
I 1 (4) 1 (2) 2 (3)
II 9 (33) 21 (51) 30 (44)
III 17 (63) 19 (46) 36 (53)
IV 0 0 0
6MWD ¼ 6-minute walking distance; CTEPH ¼ chronic thromboembolic pulmonary hypertension; PAH ¼ pulmonary arterial hypertension; WHO FC ¼World Health
Organization functional class.
Data are number (%) or mean (range). The values listed for 6MWD and WHO FC correspond to values at the end of the initial 12-week study. a n ¼ 39; b n ¼ 66.
M. Halank et al. / Respiratory Medicine 128 (2017) 50e5652patients with PAH than in those with CTEPH. Baseline WHO FC was
also slightly worse in patients with PAH than in those with CTEPH.
Thirty-six patients (53%) were still receiving riociguat treatment
at the ﬁnal data cut-off (September 2014), and 32 (47%) had dis-
continued treatment (Fig. 1). The time to discontinuation of rioci-
guat from all causes is shown in Fig. 2. At the ﬁnal data cut-off, the
median treatment duration was 77 months (range 3e87 months).
At the end of the LTE or at withdrawal, 50 (74%) patients were
receiving the maximum 2.5 mg tid dose of riociguat.
At entry to the LTE, six (9%) patients were receiving concomitant
therapy with bosentan; the remaining patients were treatment
naïve. During the course of the LTE, a further 30 (44%) patients
initiated concomitant therapy with ERAs and/or prostanoids. The
remaining 32 (47%) patients remained on riociguat monotherapy
until the ﬁnal data cut-off or discontinuation. Of the 36 patients
who were still receiving riociguat at the ﬁnal data cut-off, 16 (44%)
were receiving concomitant therapy with ERAs and/or prostanoids.3.2. Safety
A summary of riociguat safety data from the LTE is shown in
Table 2. AEs were reported by 93% of patients and were evenly
distributed across patients with PAH and CTEPH. Themost common
AEs were nasopharyngitis (57%; 0% considered drug-related) and
peripheral edema (37%; 3% considered drug-related).
Serious adverse events (SAEs) were reported by 76% of patients
and were more common amongst patients with CTEPH compared
with PAH (83% vs 67%, respectively). The most common SAEs were
right ventricular failure, syncope, and worsening PH (each occur-
ring in 19% of patients). Three (4%) cases of syncope and two (3%)
cases of worsening PH were considered drug-related. Three pa-
tients (4%) experienced SAEs of hemoptysis (all patients with PAH);
two of the SAEs of hemoptysis were moderate in severity, and one
was severe; none were considered drug-related and none were
fatal. The exposure-adjusted incidence of hemoptysis SAEs in the
LTE was 1.0 event per 100 patient-years.
Fig. 2. KaplaneMeier plot of time to discontinuation of riociguat for the 68 patients who entered the LTE.
CTEPH ¼ chronic thromboembolic pulmonary hypertension; LTE ¼ long-term extension; PAH ¼ pulmonary arterial hypertension.
Table 2
Summary of safety.






Any AE 26 (96) 37 (90) 63 (93)
M. Halank et al. / Respiratory Medicine 128 (2017) 50e56 53Six (9%) patients discontinued riociguat due to AEs as the pri-
mary reason. These were clinical worsening of PH (n ¼ 2), clinical
worsening of PAH (n ¼ 1), pneumonia (n ¼ 1), hepatocellular car-
cinoma (n ¼ 1), and headache, symptomatic ﬂush, and vertigo
related to a vascular event (n ¼ 1).AEs occurring in ≥15% of the total population
Nasopharyngitis 15 (56) 24 (59) 39 (57)
Peripheral edema 9 (33) 16 (39) 25 (37)
Dizziness 13 (48) 10 (24) 23 (34)
Worsening PH 7 (26) 15 (37) 22 (32)
Edema 5 (19) 13 (32) 18 (26)
Cough 6 (22) 11 (27) 17 (25)
Hypotension 6 (22) 10 (24) 16 (24)
Respiratory tract infection 3 (11) 11 (27) 14 (21)
Syncope 6 (22) 7 (17) 13 (19)
Right ventricular failure 7 (26) 6 (15) 13 (19)
Diarrhea 5 (19) 7 (17) 12 (18)
Anemia 4 (15) 8 (20) 12 (18)
Worsening PAH 8 (30) 4 (10) 12 (18)3.3. Secondary outcomes: long-term change from baseline in
efﬁcacy
3.3.1. 6MWD
The change from baseline in 6MWD during the LTE, in patients
who remained on riociguat therapy at each timepoint, is shown in
Fig. 3. Mean ± standard deviation (SD) 6MWD increased from
baseline by 69 ± 105 m (n ¼ 42) in the overall population at Month
48, and by 87 ± 138 m (n ¼ 15) and 59 ± 82 m (n ¼ 27) in patients
with PAH and CTEPH, respectively.Bronchitis 4 (15) 7 (17) 11 (16)
Hypokalemia 1 (4) 10 (24) 11 (16)
Nausea 5 (19) 6 (15) 11 (16)
Gastroesophageal reﬂux disease 3 (11) 7 (17) 10 (15)
Vomiting 5 (19) 5 (12) 10 (15)
Any SAE 18 (67) 34 (83) 52 (76)
SAEs occurring in ≥10% of the total population
Right ventricular failure 7 (26) 6 (15) 13 (19)
Syncope 6 (22) 7 (17) 13 (19)
Worsening PH 1 (4) 12 (29) 13 (19)
Worsening PAH 6 (22) 3 (7) 9 (13)3.3.2. WHO FC
Change from baseline in WHO FC up to Month 48 of the LTE, in
patients who remained on riociguat therapy at each timepoint, is
shown in Fig. 4. At Month 48, WHO FC had improved/stabilized/
worsened versus baseline in 50/45/5% of the overall population
(n ¼ 44), 56/44/0% of patients with PAH (n ¼ 16), and 46/46/7% of
patients with CTEPH (n ¼ 28).Cardiac failure 6 (22) 2 (5) 8 (12)
Discontinuation due to AE 4 (15) 2 (5) 6 (9)
Deathsb 5 (19) 6 (15) 11 (16)
AE ¼ adverse event; CTEPH ¼ chronic thromboembolic pulmonary hypertension;
LTE ¼ long-term extension; PAH ¼ pulmonary arterial hypertension;
PH ¼ pulmonary hypertension; SAE ¼ serious adverse event.
a Median treatment duration was 77 months (range 3e87 months).
b Two additional patients died after discontinuing riociguat.3.3.3. Survival and clinical worsening
The frequency of clinical worsening events during the LTE are
shown in Table 3. In total, 43 out of 68 (63%) patients experienced
clinical worsening events. Start of new PH treatment was the most
frequent event, occurring in 35 (51%) patients. Rates of patients in
the overall populationwho had not begun a new PH treatment at 9,
36, and 72 months were 78%, 53%, and 42%, respectively.
A total of 13 out of 68 (19%) patients died during the LTE,
including two patients who died after discontinuing riociguat. All
causes of death were assessed as being unrelated to study drug and
eight (12%) were due to progression of PAH or CTEPH, including ﬁve
cases of right heart failure. Fig. 5 shows KaplaneMeier plots of
survival and clinical worsening-free survival during the LTE. Clin-
ical worsening-free survival rates in the overall population at 9, 36,
and 72 months were 73%, 49%, and 35%, respectively. Survival rates
in the overall population at 9, 36, and 72 months were 97%, 91%,
and 81%, respectively. For the KaplaneMeier analyses, patients
were censored if they had withdrawn without experiencing an
event.4. Discussion
In an initial 12-week Phase II study, treatment with riociguat
was well tolerated and led to signiﬁcant improvements in 6MWD
and WHO FC from baseline in patients with PAH and inoperable
CTEPH [15]. Herewe show that riociguat waswell tolerated bymost
patients in the LTE phase of this study, over a median treatment
duration of >6 years. In addition, improvements in 6MWD and
WHO FC were apparently maintained for up to 4 years. No new
safety signals were identiﬁed in this LTE study and the majority of
AEs were consistent with the underlying disease and the mode of
Fig. 3. Change from baseline in 6MWD.
6MWD ¼ 6-minute walking distance; BL ¼ baseline; CTEPH ¼ chronic thromboembolic pulmonary hypertension; LTE ¼ long-term extension; PAH ¼ pulmonary arterial hyper-
tension; SEM ¼ standard error of the mean.
Data shown are observed values (mean ± SEM); missing data were not imputed.
Fig. 4. Change from baseline in WHO FC.
CTEPH ¼ chronic thromboembolic pulmonary hypertension; PAH ¼ pulmonary arterial hypertension; WHO FC ¼ World Health Organization functional class.
Data shown are observed values; missing data were not imputed. Baseline was deﬁned as the start of the initial 12-week study.
Percentages may not add up to 100% due to rounding of data.
M. Halank et al. / Respiratory Medicine 128 (2017) 50e5654action of riociguat. The safety proﬁle of riociguat was similar to that
observed during the initial 12-week trial and other riociguat clin-
ical trials [15e19].
Three patients (4%) reported SAEs of hemoptysis in this study
(two of which were moderate in severity and one of which was
severe). This is in keeping with the Phase III LTE studies of riociguat,
in which SAEs of hemoptysis or pulmonary hemorrhage were re-
ported in 3% (PATENT-2) and 2% (CHEST-2) of patients during me-
dian treatment durations of 32months and 27months, respectively
[18,19]. The exposure-adjusted incidence of hemoptysis SAEs in the
current study (1.0 event per 100 patient-years) was also broadly
consistent with results from the Phase III LTE studies (1.7 and 0.7
events per 100 patient-years in PATENT-2 and CHEST-2, respec-
tively). The potentially increased risk of respiratory tract bleeding
AEs with riociguat is reﬂected as a warning in the riociguat label
[20,21]. Hemoptysis and pulmonary hemorrhage are known com-
plications of pulmonary hypertension [22,23], and the incidence of
hemoptysis in the current study was comparable to previous re-
ports. For example, in a previous study of 210 patients with non-Eisenmenger PAH, moderate-to-severe hemoptysis was observed
in 12 (6%) patients seen over a period of 10 years [23], while in
another study of 79 patients with CTEPH, ﬁve (6%) patients suffered
from moderate-to-severe hemoptysis requiring medical interven-
tion [24].
There was a relatively high rate of clinical worsening observed
in this study; the rates of clinical worsening-free survival at 9, 36,
and 72 months were 73%, 49%, and 35%, respectively. As a com-
parison, the 2-year rates of clinical worsening-free survival in the
PATENT-2 and CHEST-2 studies were 79% and 82%, respectively
[18,19]. However, the high rate of clinical worsening in this study
was driven primarily by patients starting new PH treatment, which
may reﬂect the fact that riociguat was at a relatively early stage of
development at the time this study was conducted, and that the
study was performed in Germany where PH-speciﬁc therapies are
readily available. In keeping with this, the clinical worsening event
“start of new PH treatment” occurred more frequently in this study
(51% of patients as a ﬁrst event [11.3 cases per 100 patient-years])
than in the PATENT-2 and CHEST-2 studies (18% [11.1 cases per
Table 3
Frequency of clinical worsening events. For patients with more than one event, only the ﬁrst event is shown.
Event, n (%) PAH (n ¼ 27) CTEPH (n ¼ 41) All patients (n ¼ 68)
Patients with clinical worsening event 17 (63) 26 (63) 43 (63)
PEA 0 6 (15) 6 (9)
Start of new PH treatment 16 (59) 19 (46) 35 (51)
Deathsa 1 (4) 1 (2) 2 (3)
CTEPH ¼ chronic thromboembolic pulmonary hypertension; PAH ¼ pulmonary arterial hypertension; PEA ¼ pulmonary endarterectomy; PH ¼ pulmonary hypertension.
Median treatment duration was 77 months (3e87 months).
a This ﬁgure differs from the 13 deaths reported in the text because only the ﬁrst event experienced by a patient is shown.
Fig. 5. KaplaneMeier plots of (A) survival and (B) clinical worsening-free survival. Patients were censored if they had withdrawn without experiencing an event.
CTEPH ¼ chronic thromboembolic pulmonary hypertension; PAH ¼ pulmonary arterial hypertension.
M. Halank et al. / Respiratory Medicine 128 (2017) 50e56 55100 patient-years] and 10% [5.0 cases per 100 patient-years],
respectively, of patients overall [18,19]). Despite the high rate of
clinical worsening, survival rates in this study compared favorably
with those observed in the PATENT-2 and CHEST-2 studies. Survival
rates in the overall study population at 9, 36, and 72 months, with
patients censored if they had withdrawn, were 97%, 91%, and 81%,
respectively, compared with 93% at 2 years in both PATENT-2 and
CHEST-2 [18,19].
There was also a relatively high drop-out rate during the study,with 47% of patients discontinuing treatment by the ﬁnal cut-off.
This is likely to reﬂect the long duration of treatment (median 77
months) and the fact that riociguat was an experimental drug at the
time the study was conducted (increasing the likelihood of with-
drawn consent by the patient or physician). As a comparison, the
withdrawal rates in the PATENT-2 and CHEST-2 Phase III LTE studies
were 31% and 27%, respectively, but with signiﬁcantly shorter
treatment durations (median durations of 32 months in PATENT-2
and 27 months in CHEST-2) [18,19].
M. Halank et al. / Respiratory Medicine 128 (2017) 50e5656The current study has certain limitations which are common to
most LTE studies. These include the lack of a placebo group, a drop-
out rate of 47% during the LTE, and the fact that approximately 50%
of patients were receiving concomitant therapy during the course
of the LTE, making it difﬁcult to unequivocally attribute the safety
and efﬁcacy ﬁndings solely to riociguat. In addition, patient drop-
out may have resulted in bias towards those who responded well
to riociguat treatment.
5. Conclusions
Riociguat was generally well tolerated over a median treatment
duration of >6 years in patients with PAH and inoperable CTEPH in
this Phase II LTE study. No new safety signals were identiﬁed, and
improvements in 6MWD and WHO FC were maintained at 4 years
in patients who remained on treatment. These data support rioci-
guat as a favorable long-term treatment option for patients with
PAH and inoperable CTEPH.
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